Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 17, 2008

View Archived Issues

Y's Therapeutics and Kissei sign Japanese licensing agreement for YSCMA

XenoPort to initiate a phase II clinical trial of XP1-9986 in acute back spasms

Tuberculosis vaccine VPM-1002 enters phase I investigation

Beneficial effects seen with ivabradine in some coronary artery disease patients

FDA releases clinical hold on Novacea's Asentar IND application

CuraGen completes enrollment in phase II CR011-vcMMAE trial in melanoma

FDA places partial clinical hold on phase III GVAX program in prostate cancer

Final patient completes first phase III sodium oxybate trial in fibromyalgia

Inspire plans clinical testing of new glaucoma compound INS-117548

MAT completes enrollment in phase I/II Ferritarg trial in Hodgkin's disease

Phase II results for brivanib alaninate disclosed at the ILCA Conference

TAC-101 provides disease stabilization and prolonged survival in advanced HCC phase I/II study

Novel natural compound prevents bone loss in experimental model of osteoporosis

MedImmune enters autoimmune disease research collaboration with SBI Biotech

Positive results in aromatase-resistant breast cancer with combined sorafenib/anastrozole therapy

Oxygen sets FDA meeting date for proposed phase IIb Oxycyte trial

FDA approves Gamunex for inflammatory demyelinating polyneuropathy

Novel treatment options for obesity described in recent patents

AstraZeneca and Targacept report results from phase IIb AZD-3480 trial

New compounds for treating glaucoma disclosed in recent Allergan patent

Enanta initiates phase Ia study for oral antibiotic EDP-322

University of Southern California patent claims novel agents for osteoporosis

Othera commences phase I/II OT-730 trial in ocular hypertension and glaucoma

Phase II study evaluates Exinalda in CF patients with fat malabsorption

Xarelto approved in Canada for prevention of venous thromboembolic events

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...